A new analgesic agent based on hexaazaisowurzitan: feasibility of using in managing patients with cancer
Purpose: to study gastrotoxic and ulcerogenic effects of a long-term administration of a newly synthesized compound from the hexaazaisowurzitan (thiowurtzine) series in rats, as well as to assess its effect on the transplantable tumor in mice.Material and Methods. Lewis lung carcinoma was transplant...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2020-04-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/1402 |
| _version_ | 1797875825919393792 |
|---|---|
| author | K. A. Lopatina S. G. Krylova E. A. Safonova E. P. Zueva D. A. Kulagina А. A. Churin T. I. Fomina S. V. Sysolyatin |
| author_facet | K. A. Lopatina S. G. Krylova E. A. Safonova E. P. Zueva D. A. Kulagina А. A. Churin T. I. Fomina S. V. Sysolyatin |
| author_sort | K. A. Lopatina |
| collection | DOAJ |
| description | Purpose: to study gastrotoxic and ulcerogenic effects of a long-term administration of a newly synthesized compound from the hexaazaisowurzitan (thiowurtzine) series in rats, as well as to assess its effect on the transplantable tumor in mice.Material and Methods. Lewis lung carcinoma was transplanted into mice, and thiowurtzine was prescribed for a long course together with cyclophosphamide. In the terminal stage of tumor development the mass of the primary node, the number and area of metastases in the lungs of mice were measured. Histological sections of the stomach were studied in rats after a 90-day administration of thiowurtzine.Results. Thiowurtzine at therapeutic dosages of 50 and 100 mg/kg for a course of 19 days potentiated the effect of cyclophosphamide to inhibit tumor dissemination and exerted a direct antitumor effect in mice with lewis lung carcinoma. A dose of 1000 mg/kg for 90 days did not cause ulcerogenic action of thiowurtzine.Conclusion. The absence of a stimulating effect on tumor growth in animal experiments and intactness in relation to the gastric mucosa during chronic administration of thiowurtzine allow us to recommend this innovative analgesic for clinical study as a concomitant analgesia in cancer patients. |
| first_indexed | 2024-04-10T01:52:40Z |
| format | Article |
| id | doaj.art-e0ed02ed56234b63a6fdfa11e2c54182 |
| institution | Directory Open Access Journal |
| issn | 1814-4861 2312-3168 |
| language | Russian |
| last_indexed | 2024-04-10T01:52:40Z |
| publishDate | 2020-04-01 |
| publisher | Russian Academy of Sciences, Tomsk National Research Medical Center |
| record_format | Article |
| series | Сибирский онкологический журнал |
| spelling | doaj.art-e0ed02ed56234b63a6fdfa11e2c541822023-03-13T09:05:53ZrusRussian Academy of Sciences, Tomsk National Research Medical CenterСибирский онкологический журнал1814-48612312-31682020-04-01192768110.21294/1814-4861-2020-19-2-76-81731A new analgesic agent based on hexaazaisowurzitan: feasibility of using in managing patients with cancerK. A. Lopatina0S. G. Krylova1E. A. Safonova2E. P. Zueva3D. A. Kulagina4А. A. Churin5T. I. Fomina6S. V. Sysolyatin7Научно-исследовательский институт фармакологии и регенеративной медицины имени Е.Д. Гольдберга, Томский национальный исследовательский медицинский центр, Российская академия наукНаучно-исследовательский институт фармакологии и регенеративной медицины имени Е.Д. Гольдберга, Томский национальный исследовательский медицинский центр, Российская академия наукНаучно-исследовательский институт фармакологии и регенеративной медицины имени Е.Д. Гольдберга, Томский национальный исследовательский медицинский центр, Российская академия наукНаучно-исследовательский институт фармакологии и регенеративной медицины имени Е.Д. Гольдберга, Томский национальный исследовательский медицинский центр, Российская академия наукФедеральное государственное бюджетное учреждение науки «институт проблем химико-энергетических технологий, Сибирское отделение Российской академии наукНаучно-исследовательский институт фармакологии и регенеративной медицины имени Е.Д. Гольдберга, Томский национальный исследовательский медицинский центр, Российская академия наукНаучно-исследовательский институт фармакологии и регенеративной медицины имени Е.Д. Гольдберга, Томский национальный исследовательский медицинский центр, Российская академия наукФедеральное государственное бюджетное учреждение науки «институт проблем химико-энергетических технологий, Сибирское отделение Российской академии наукPurpose: to study gastrotoxic and ulcerogenic effects of a long-term administration of a newly synthesized compound from the hexaazaisowurzitan (thiowurtzine) series in rats, as well as to assess its effect on the transplantable tumor in mice.Material and Methods. Lewis lung carcinoma was transplanted into mice, and thiowurtzine was prescribed for a long course together with cyclophosphamide. In the terminal stage of tumor development the mass of the primary node, the number and area of metastases in the lungs of mice were measured. Histological sections of the stomach were studied in rats after a 90-day administration of thiowurtzine.Results. Thiowurtzine at therapeutic dosages of 50 and 100 mg/kg for a course of 19 days potentiated the effect of cyclophosphamide to inhibit tumor dissemination and exerted a direct antitumor effect in mice with lewis lung carcinoma. A dose of 1000 mg/kg for 90 days did not cause ulcerogenic action of thiowurtzine.Conclusion. The absence of a stimulating effect on tumor growth in animal experiments and intactness in relation to the gastric mucosa during chronic administration of thiowurtzine allow us to recommend this innovative analgesic for clinical study as a concomitant analgesia in cancer patients.https://www.siboncoj.ru/jour/article/view/1402анальгезияопухольтиовюрцингексаазаизовюрцитанкарцинома легких льюиса |
| spellingShingle | K. A. Lopatina S. G. Krylova E. A. Safonova E. P. Zueva D. A. Kulagina А. A. Churin T. I. Fomina S. V. Sysolyatin A new analgesic agent based on hexaazaisowurzitan: feasibility of using in managing patients with cancer Сибирский онкологический журнал анальгезия опухоль тиовюрцин гексаазаизовюрцитан карцинома легких льюиса |
| title | A new analgesic agent based on hexaazaisowurzitan: feasibility of using in managing patients with cancer |
| title_full | A new analgesic agent based on hexaazaisowurzitan: feasibility of using in managing patients with cancer |
| title_fullStr | A new analgesic agent based on hexaazaisowurzitan: feasibility of using in managing patients with cancer |
| title_full_unstemmed | A new analgesic agent based on hexaazaisowurzitan: feasibility of using in managing patients with cancer |
| title_short | A new analgesic agent based on hexaazaisowurzitan: feasibility of using in managing patients with cancer |
| title_sort | new analgesic agent based on hexaazaisowurzitan feasibility of using in managing patients with cancer |
| topic | анальгезия опухоль тиовюрцин гексаазаизовюрцитан карцинома легких льюиса |
| url | https://www.siboncoj.ru/jour/article/view/1402 |
| work_keys_str_mv | AT kalopatina anewanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer AT sgkrylova anewanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer AT easafonova anewanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer AT epzueva anewanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer AT dakulagina anewanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer AT aachurin anewanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer AT tifomina anewanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer AT svsysolyatin anewanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer AT kalopatina newanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer AT sgkrylova newanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer AT easafonova newanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer AT epzueva newanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer AT dakulagina newanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer AT aachurin newanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer AT tifomina newanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer AT svsysolyatin newanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer |